Compare Cardinal Health Inc (CAH) vs Diageo plc (DEO) Price & Performance

Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.

The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.

Diageo (DEO) trades at $93.96, down 3.24% today, with mixed technical signals showing bullish moving averages but overbought RSI readings. The company reported FY2026 results with organic sales declining 2% but operating profit increasing 2% through cost savings. Recent news highlights a $1 billion cost-cutting plan and strategic reset under new CEO Dave Lewis, driving investor optimism despite North American weakness.

The outlook remains cautiously optimistic with analyst consensus leaning buy (49%) as cost savings and cash generation initiatives offset regional challenges. Key risks include persistent North American sales pressure and execution risks on the turnaround plan, while valuation metrics suggest premium pricing relative to historical levels.